Gianluca Tomasello

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Fotios Loupakis, Carlotta Antoniotti et al. · The Lancet Oncology · 2015 · 1.1K citations · Full text

Phase 3, Gastrointestinal Oncology, Medicine +8

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

Fotios Loupakis, Chiara Cremolini, Gianluca Masi et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer

Fausto Petrelli, Gianluca Tomasello, Karen Borgonovo et al. · JAMA Oncology · 2016 · 722 citations

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Giovanni Fucà, Vincenzo Guarini, Carlotta Antoniotti et al. · British Journal of Cancer · 2020 · 315 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8